Need pharma insights? Register for Evaluate Discovery
Menu
Menu
In an ever-evolving market landscape, understanding the intricacies of clinical and commercial differentiation is the key to achieving success. We design our comprehensive suite of solutions and insights to give you the competitive edge you need to navigate the market’s complexities, prioritise opportunities, and make your next move the most impactful.
Track disease stages, sub-populations, and treatment flow, allowing you to benchmark your forecasts against potential and addressable market data. Estimate drug-treated populations with our bottom-up forecasting to understand population evolution, validate investments, and identify growth opportunities.
Understand the pharmaceutical market’s past, present, and future performance with over two decades of commercial data and a continually extending window of consensus forecasts. Access a richer view that uniquely links consensus forecasts to pipelines across indications, therapeutic areas, and mechanisms of action.
Put the power of machine learning to work. Analyse millions of data points across the full clinical pipeline to discern critical connections between risk and return. Highlight promising drugs and forecast R&D expenses, drug prices, and market entry timelines like never before.
Leveraging a foundation of extensive Evaluate data, augmented with secondary research, modelling and analysis, our pharmaceutical consulting solutions are data-driven and insight-focused.
Know which opportunities and markets offer the highest growth potential. Focus your resources strategically.
Find and validate pharma opportunities with a robust assessment of market fit, risk, uptake and sales forecasts, and more.
Build a better understanding of your growth drivers and product differentiators with a clear analysis of market dynamics, trends, unmet needs, and competitors.
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
If you missed our recent webinar in which we dived in the orphan drugs landscape, you skipped a fascinating discussion between biopharma journalist Melanie Senior, author of our recent report...
You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t...
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the...
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up....
300 million people worldwide are living with a rare disease. The “orphan” drugs created to treat them have been a fast-growing part of the pharma market for years – and...
To those beyond the world of biopharma, the term “orphan drug” sounds a bit sad, a bit forgotten. But to those involved in the industry, the superior return on investment,...
